MicroRNA as a New Factor in Lung and Esophageal Cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 24, Issue 3, 2012, Pages 155-165

  Billeter, Adrian T ^a   Barnett, Rebecca E ^b   Druen, Devin ^a   Polk, Hiram C ^a   Van Berkel, Victor H ^a  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Biomarker; Cancer; Esophageal cancer; Lung cancer; MicroRNA; MiRNA

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 106A; MICRORNA 126; MICRORNA 140; MICRORNA 141; MICRORNA 145; MICRORNA 152; MICRORNA 155; MICRORNA 182; MICRORNA 197; MICRORNA 19B; MICRORNA 200; MICRORNA 20A; MICRORNA 20B; MICRORNA 21; MICRORNA 210; MICRORNA 222; MICRORNA 223; MICRORNA 24; MICRORNA 25; MICRORNA 28; MICRORNA 301; MICRORNA 30C; MICRORNA 30E; MICRORNA 375; MICRORNA 486; MICRORNA 660; MICRORNA 92A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SCREENING; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; EARLY DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT TRANSFORMATION; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RNA TRANSPORT; SENSITIVITY AND SPECIFICITY; SYSTEMIC THERAPY; TUMOR DIFFERENTIATION;

EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GENETIC THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MICRORNAS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870465429     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2012.06.009     Document Type: Article

References (67)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Richards M.A. The size of the prize for earlier diagnosis of cancer in England. Br J Cancer 2009, 101(suppl 2):S125-S129.
3. Aberle D.R., Adams A.M., Berg C.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
4. Diederich S., Wormanns D., Semik M., et al. Screening for early lung cancer with low-dose spiral CT: Prevalence in 817 asymptomatic smokers. Radiology 2002, 222:773-781.
5. Vega K.J., Jamal M.M. Changing pattern of esophageal cancer incidence in New Mexico. Am J Gastroenterol 2000, 95:2352-2356.
6. Lagergren J., Bergström R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825-831.
7. Barrett N.R. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg 1950, 38:175-182.
8. Hofstetter W.L., Peters J.H., DeMeester T.R., et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 2001, 234:532-538. [discussion:538-539].
9. Luna R.A., Gilbert E., Hunter J.G. High-grade dysplasia and intramucosal adenocarcinoma in Barrett's esophagus: The role of esophagectomy in the era of endoscopic eradication therapy. Curr Opin Gastroenterol 2012, 28:362-369.
10. Billeter A.T., Druen D., Kanaan Z.M., et al. miRNAs: New helpers for surgeons?. Surgery 2012, 151:1-5.
11. He L., He X., Lowe S.W., et al. miRNAs join the p53 network-Another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007, 7:819-822.
12. O'Neill L.A., Sheedy F.J., McCoy C.E. miRNAs: The fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011, 11:163-175.
13. Tili E., Croce C.M., Michaille J.J. miR-155: On the crosstalk between inflammation and cancer. Int Rev Immunol 2009, 28:264-284.
14. Weber J.A., Baxter D.H., Zhang S., et al. The miRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
15. Gilad S., Meiri E., Yogev Y., et al. Serum miRNAs are promising novel biomarkers. PLoS ONE 2008, 3:e3148.
16. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: miRNAs can up-regulate translation. Science 2007, 318:1931-1934.
17. Hayashita Y., Osada H., Tatematsu Y., et al. A polycistronic miRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005, 65:9628-9632.
18. Chen X., Liang H., Zhang J., et al. Horizontal transfer of miRNAs: Molecular mechanisms and clinical applications. Protein Cell 2012, 3:28-37.
19. Molnar A., Melnyk C.W., Bassett A., et al. Small silencing RNAs in plants are mobile and direct epigenetic modification in recipient cells. Science 2010, 328:872-875.
20. Jose A.M., Garcia G.A., Hunter C.P. Two classes of silencing RNAs move between Caenorhabditis elegans tissues. Nat Struct Mol Biol 2011, 18:1184-1188.
21. Valiunas V., Polosina Y.Y., Miller H., et al. Connexin-specific cell-to-cell transfer of short interfering RNA by gap junctions. J Physiol 2005, 568:459-468.
22. Hosoda T., Zheng H., Cabral-da-Silva M., et al. Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation 2011, 123:1287-1296.
23. Lim P.K., Bliss S.A., Patel S.A., et al. Gap junction-mediated import of miRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 2011, 71:1550-1560.
24. Balaj L., Lessard R., Dai L., et al. Tumour mivesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011, 2:180.
25. Turchinovich A., Weiz L., Langheinz A., et al. Characterization of extracellular circulating miRNA. Nucleic Acids Res 2011, 39:7223-7233.
26. Vickers K.C., Palmisano B.T., Shoucri B.M., et al. miRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13:423-433.
27. Izquierdo-Useros N., Naranjo-Gómez M., Archer J., et al. Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood 2009, 113:2732-2741.
28. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A 2010, 107:6328-6333.
29. Bronisz A., Godlewski J., Wallace J.A., et al. Reprogramming of the tumour mienvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 2012, 14:159-167.
30. Zhang H.G., Grizzle W.E. Exosomes and cancer: A newly described pathway of immune suppression. Clin Cancer Res 2011, 17:959-964.
31. Kogure T., Lin W.L., Yan I.K., et al. Intercellular nanovesicle-mediated miRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011, 54:1237-1248.
32. Silva J., Garcia V., Zaballos A., et al. Vesicle-related miRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011, 37:617-623.
33. Shen J., Todd N.W., Zhang H., et al. Plasma miRNAs as potential biomarkers for non-small-cell lung cancer. Lab Investig J Tech Methods Pathol 2011, 91:579-587.
34. Zheng D., Haddadin S., Wang Y., et al. Plasma miRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011, 4:575-586.
35. Shen J., Liu Z., Todd N.W., et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma miRNA biomarkers. BMC Cancer 2011, 11:374.
36. Wei J., Gao W., Zhu C.J., et al. Identification of plasma miRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011, 30:407-414.
37. Boeri M., Verri C., Conte D., et al. miRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011, 108:3713-3718.
38. Chen X., Hu Z., Wang W., et al. Identification of ten serum miRNAs from a genome-wide serum miRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012, 130:1620-1628.
39. Liu X.G., Zhu W.Y., Huang Y.Y., et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012, 29:618-626.
40. Roth C., Kasimir-Bauer S., Pantel K., et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 2011, 5:281-291.
41. Foss K.M., Sima C., Ugolini D., et al. miR-1254 and miR-574-5p: Serum-based miRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011, 6:482-488.
42. Chen X., Ba Y., Ma L., et al. Y, Ma L, et al. Characterization of miRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
43. Hennessey P.T., Sanford T., Choudhary A., et al. Serum miRNA biomarkers for detection of non-small cell lung cancer. PLoS ONE 2012, 7:e32307.
44. Lin Q., Mao W., Shu Y., et al. A cluster of specified miRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol 2012, 138:85-93.
45. Bianchi F., Nicassio F., Marzi M., et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO molecular medicine 2011, 3:495-503.
46. Xie Y., Todd N.W., Liu Z., et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67:170-176.
47. Keller A., Leidinger P., Gislefoss R., et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol 2011, 8:506-516.
48. Lu J., Getz G., Miska E.A., et al. miRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
49. Lu Y., Govindan R., Wang L., et al. miRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 2012, 33:1046-1054.
50. Landi M.T., Zhao Y., Rotunno M., et al. miRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010, 16:430-441.
51. Garofalo M., Romano G., Di Leva G., et al. EGFR and MET receptor tyrosine kinase-altered miRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012, 18:74-82.
52. Feng B., Wang R., Song H.Z., et al. miRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 2012, 118:3365-3376.
53. Hu Z Chen X., Zhao Y., et al. Serum miRNA signatures identified in a genome-wide serum miRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28:1721-1726.
54. Wang Z.X., Bian H.B., Wang J.R., et al. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol 2011, 104:847-851.
55. Gao W., Lu X., Liu L., et al. MiRNA-21: A biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012, 13:330-340.
56. DeMeester S.R. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res 2009, 3:S2-S5.
57. Zhang C., Wang C., Chen X., et al. Expression profile of miRNAs in serum: A fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010, 56:1871-1879.
58. Komatsu S., Ichikawa D., Takeshita H., et al. Circulating miRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011, 105:104-111.
59. Bansal A., Lee I.H., Hong X., et al. Feasibility of miRNAs as biomarkers for Barrett's esophagus progression: A pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol 2011, 106:1055-1063.
60. Maru D.M., Singh R.R., Hannah C., et al. miRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol 2009, 174:1940-1948.
61. Wijnhoven B.P., Hussey D.J., Watson D.I., et al. miRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg 2010, 97:853-861.
62. Guo Y., Chen Z., Zhang L., et al. Distinctive miRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008, 68:26-33.
63. Hu Y., Correa A.M., Hoque A., et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 2011, 128:132-143.
64. Feber A., Xi L., Pennathur A., et al. miRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg 2011, 91:1523-1530.
65. Mathé E.A., Nguyen G.H., Bowman E.D., et al. miRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res 2009, 15:6192-6200.
66. Galandiuk S., Rodriguez-Justo M., Jeffery R., et al. Field cancerization in the intestinal epithelium of patients with Crohn's ileocolitis. Gastroenterology 2012, 142:855-864. e858.
67. Wang J., Chen J., Chang P., et al. miRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer. Prev Res (Phila) 2009, 2:807-813.